Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) saw an upside of 0.35% to close Tuesday at $180.21 after adding $0.63 on the day. The 5-day average trading volume is 1,425,240 shares of the company’s common stock. It has gained $182.58 in the past week. An average of 1,458,825 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,643,578.
VRTX’s 1-month performance is -5.51% or -$8.36 on its low of $176.36 reached on 10/06/21. The company’s shares have touched a 52-week low of $176.36 and high of $280.99, with the stock’s rally to the 52-week high happening on 01/25/21. YTD, VRTX has lost -23.75% or -$56.13. However, the current price is down -35.87%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Jun 02, 133 days have gone by since the last insider trading activity for Vertex Pharmaceuticals Incorporated (VRTX). Bhatia Sangeeta N. (Director) most recently sold 559 shares at $209.69 per share on Jun 02. This transaction cost the insider $117,216. EVP, Chief Comm & Ops Officer, Arbuckle Stuart A, sold 109 shares at a price of $216.41 on May 17. Then, on May 17, EVP, Global Research and CSO ALTSHULER DAVID sold 79 shares at a price of $216.36 per share. This transaction amounted to $17,093.
The company’s PE ratio for the last five years has touched a high of 199.42 and a low of 17.86. VRTX stock has a beta of 0.62. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 7.04 while the price-to-book (PB) in the most recent quarter is 5.07, with the price to cash flow ratio at 26.46.
Vertex Pharmaceuticals Incorporated’s quick ratio for the period ended June 29 was 4.40, with the current ratio over the same period at 4.60 meaning that VRTX stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.06, while the total debt to equity was 0.00. In terms of profitability, the gross margin trailing 12 months is 87.90%. The trailing 12-month EBITDA margin is 48.03% while for the period ending June 29; Vertex Pharmaceuticals Incorporated’s operating margin was 33.90%. The firm’s gross profit as reported stood at $5.47 billion against revenue of $6.21 billion.
For the quarterly period ending June 29 this year, Vertex Pharmaceuticals Incorporated’s cash and short-term investments amounted to $644.32 million against total debt of $893.85 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected VRTX to announce $2.51 per share in earnings in its latest quarter, but it posted $3.11, representing a 23.90% surprise. EBITDA for the quarter stood at more than -$6.72 million. VRTX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 3.03 billion, with total debt at $893.85 million. Shareholders hold equity totaling $259.43 million
Let’s look briefly at Vertex Pharmaceuticals Incorporated (VRTX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 40.97% to suggest the stock is trending Neutral, with historical volatility in this time period at 15.64%.
The stock’s 5-day moving average is $179.93, reflecting a +1.81% or $3.20 change from its current price. VRTX is currently trading -4.35% above its 20-day SMA, -16.80% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -9.13% and -23.14% respectively.
Stochastic %K and %D was 30.97% and 29.53% and the average true range (ATR) pointed at 3.14. The RSI (14) points at 38.37%, while the 14-day stochastic is at 37.97% with the period’s ATR at 3.30. The stock’s 9-day MACD Oscillator is pointing at 0.04 and -1.26 on the 14-day charts.
In the most recent analyst report for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Stifel downgraded it to a Hold rating. They previously had a Buy rating on the stock. Analysts offering their rating for VRTX stock have a consensus rating for the stock as Overweight. Currently, 2 brokerage advisors rate VRTX as a “sell,”, while 5 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 3 rates the stock as overweight while 17 have offered a “buy” rating.
What is VRTX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $175.00 and a high of $331.00, with their median price target at $260.00. Looking at these predictions, the average price target given by analysts is for Vertex Pharmaceuticals Incorporated (VRTX) stock is $260.52.